Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...
In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...
"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...
Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...
Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...
On July 12, 2022, Beilu participated in the seventh batch of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use Joint Procurement Off...
Young and middle-aged people face more problems in life, work, and emotion. So they are prone to anxiety, which can lead to high blood pressure. Therefore, it is important to control and relieve the a...